Archive · 19 Nov 2025
Pfizer Launches Rimegepant for Migraine Relief in India
Pfizer has launched a new medicine called Rimegepant in India to help people with migraines feel better faster.
It works differently than other medicines by targeting something called CGRP.
Pfizer hopes this will help people with migraines manage their pain better and get back to their daily lives quicker.
The company is excited about this new treatment and believes it will make a big difference for people living with migraines in India.
Pfizer introduces Rimegepant, a new oral medication for migraine treatment in India
Rimegepant targets calcitonin gene-related peptide (CGRP) for rapid pain relief
Meenakshi Nevatia, Pfizer Ltd. India's Managing Director, expresses excitement about the launch
Pfizer aims to help migraine patients manage pain more effectively and reclaim productive days
Rimegepant sets a new standard in comprehensive migraine care in the Indian market
- Who
- Pfizer Ltd., India
- What
- Launched Rimegepant, a new oral medication for migraine treatment
- When
- Recently
- Where
- India
- Why
- To provide rapid and effective relief for migraine patients
- Medication Name
- Rimegepant
- Target
- Calcitonin gene-related peptide (CGRP)
- Purpose
- Migraine treatment and pain relief
- Launching Company
- Pfizer Ltd., India
- Managing Director's Statement
- We are excited to bring Rimegepant to India. Its potential impact on people living with migraine will be tremendous.